Forty-one patients with epithelial ovarian tumors of low malignant potential are discussed.

Previously, we reported that PN expression is up-regulated in epithelial ovarian tumors.

The study analyzed biospecimens from 20 human patients with epithelial ovarian cancer.

By contrast, little is known about the etiology of epithelial ovarian cancer.

Limited data are available regarding this pathway in epithelial ovarian cancer.

I have epithelial ovarian cancer which is the most common type.

Our data suggest that histologic types of epithelial ovarian cancer are etiologically distinct.

We hypothesized that clinically relevant molecular switch genes exist in epithelial ovarian cancer.

Carboplatin plus paclitaxel remains the standard of care for advanced epithelial ovarian cancer.

Thirty-eight women with epithelial ovarian cancer were treated with gemcitabine, a new antimetabolite.

The volunteers had recurrent epithelial ovarian, primary peritoneal, or Fallopian-tube cancer.

Purpose: Treatment of multi-resistant epithelial ovarian cancer represents a clinical challenge with limited choices.

Angiogenesis is a proven clinical target for the treatment of advanced epithelial ovarian cancer.

Treatment of all epithelial ovarian cancer cells with docetaxel resulted in significant apoptotic death.

The activity of the antiestrogen tamoxifen was evaluated in 23 patients with epithelial ovarian carcinoma.

Conclusion: These results warrant further study of vinorelbine in patients with platinum-resistant epithelial ovarian cancer.